Zobrazeno 1 - 10
of 153
pro vyhledávání: '"Alan B, Miller"'
Autor:
Thomas Holbro, Javed Butler, Peter E. Carson, Marco Metra, Zubin J. Eapen, Piotr Ponikowski, Gerasimos Filippatos, James L. Januzzi, Rahul S. Loungani, Adriaan A. Voors, G. Michael Felker, John R. Teerlink, Peter S. Pang, Beth A. Davison, Barry H. Greenberg, Alan B. Miller, Claudio Gimpelewicz, Chien-Wei Chen, David E. Lanfear, Ileana L. Piña, Larry A. Allen, Gad Cotter
Publikováno v:
JACC: Heart Failure. 8:999-1008
Objectives This study sought to better understand the discrepant results of 2 trials of serelaxin on acute heart failure (AHF) and short-term mortality after AHF by analyzing causes of death of patients in the RELAX-AHF-2 (Efficacy, Safety and Tolera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2c4fafdf4eae7220c0e35623b1faf030
https://doi.org/10.1016/j.jchf.2020.09.010
https://doi.org/10.1016/j.jchf.2020.09.010
Autor:
Alan B Miller
Publikováno v:
Vascular Health and Risk Management, Vol Volume 3, Pp 605-609 (2007)
Alan B MillerDivision of Cardiology, University of Florida/Jacksonville, FL, USAAbstract: Aldosterone, a neurohormone known to affect electrolytes, has recently been implicated as playing a major role in the progression of heart failure, particularly
Externí odkaz:
https://doaj.org/article/db203af7730e439cba7f98208195bedc
Autor:
Marla B. Sultan, Jose Lopez-Sendon, Alan B. Miller, James L. Januzzi, Terrell A. Patterson, Balarama Gundapaneni, Blair J. O'Neill
Publikováno v:
The American journal of cardiology. 148
In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality and cardiovascular (CV)-related hospitalizations compared with placebo in patients with transthyretin amyloid cardiomyopathy (ATTR-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6239f72ae18bc9fd265eb9b33ddd3a6
https://pubmed.ncbi.nlm.nih.gov/33667442
https://pubmed.ncbi.nlm.nih.gov/33667442
Autor:
Gerasimos Filippatos, Stuart J. Pocock, Javed Butler, Peter E. Carson, Waheed Jamal, Sven Schnaidt, Stefan D. Anker, Martina Brueckmann, John R. Teerlink, Wolfram Doehner, Milton Packer, Cordula Zeller, Alan B. Miller, Faiez Zannad, S. Pehrson, Markus Haass, Inder S. Anand, Michel Komajda, João Pedro Ferreira
Publikováno v:
Circulation. 143(4)
Background: Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction, with or without diabetes, but additional data are needed about the effect of the d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::601e00dfdd2177a900fc500feae54924
https://pubmed.ncbi.nlm.nih.gov/34526679
https://pubmed.ncbi.nlm.nih.gov/34526679
Autor:
Christopher M O'Connor, Mona Fiuzat, Peter E Carson, Inder S Anand, Jonathan F Plehn, Stephen S Gottlieb, Marc A Silver, JoAnn Lindenfeld, Alan B Miller, Michel White, Ryan Walsh, Penny Nelson, Allen Medway, Gordon Davis, Alastair D Robertson, J David Port, James Carr, Guinevere A Murphy, Laura C Lazzeroni, William T Abraham, Stephen B Liggett, Michael R Bristow
Publikováno v:
PLoS ONE, Vol 7, Iss 10, p e44324 (2012)
Pharmacogenetics involves complex interactions of gene products affecting pharmacodynamics and pharmacokinetics, but there is little information on the interaction of multiple genetic modifiers of drug response. Bucindolol is a β-blocker/sympatholyt
Externí odkaz:
https://doaj.org/article/cd47e15ce88a411b9af992526484b8c4
Publikováno v:
Cardiovascular Innovations and Applications, Vol 2, Iss 3, Pp 333-345 (2017)
The Digoxin Investigation Group trial has multiple flaws in the trial design for the findings to be universally applicable. Digoxin in low serum concentrations (0.5–0.9 ng/mL) has been shown to decrease mortality in heart failure patients. Multiple
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::11dada67c439c2f53c307efad14b98dc
http://www.ingentaconnect.com/content/cscript/cvia/2017/00000002/00000003/art00003
http://www.ingentaconnect.com/content/cscript/cvia/2017/00000002/00000003/art00003
Autor:
Alan B. Miller, Cloie June L. Chiong
Publikováno v:
Journal of Cardiac Failure. 26:S127-S128
Introduction Adherence to guideline-directed therapy in heart failure patients is an important goal. Traditionally, elderly patients have difficulties attaining target doses of these therapies and this may be exaggerated in a homebound population. Hy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e0371d7dd23dbebdd39ede25d8176e7
https://doi.org/10.1016/j.cardfail.2020.09.367
https://doi.org/10.1016/j.cardfail.2020.09.367
Autor:
John Henderson, Michael M. Givertz, Kelly Axsom, Ersilia M. DeFilippis, Alan B. Miller, Philip B. Adamson, Maria Rosa Costanzo, Marie-Elena Brett
Publikováno v:
Journal of Cardiac Failure. 26:S87
Introduction Sex is often associated with divergent outcomes in cardiovascular disease. Response to pharmacologic and device-based therapy for heart failure (HF) may vary by sex, yet women are often underrepresented in clinical trials. We sought to e
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::052f8f7be37725c5b271e9219222613e
https://doi.org/10.1016/j.cardfail.2020.09.256
https://doi.org/10.1016/j.cardfail.2020.09.256
Publikováno v:
Journal of the American College of Cardiology. 75:2608
Ventricular Standstill is associated with electrolyte imbalances, increased vagal tone, and can occur post MI due to ischemia and subsequent conduction defects. A 64-year-old male presented with severe chest pain and nausea. His EKG had ST-elevations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c02cc3d55d2544efaf817d5e46734f5
https://doi.org/10.1016/s0735-1097(20)33235-6
https://doi.org/10.1016/s0735-1097(20)33235-6
Autor:
Marla B. Sultan, Balarama Gundapaneni, Jose Lopez-Sendon, Blair J. O'Neill, James Januzzi, Terrell A. Patterson, Alan B. Miller
Publikováno v:
Journal of the American College of Cardiology. 75:692
In the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR-ACT), tafamidis significantly reduced mortality and cardiovascular (CV)-related hospitalizations compared with placebo in patients with transthyretin amyloid cardiomyopathy (ATTR-C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b317ecdb741f9cad3d7bfc82d5542f6d
https://doi.org/10.1016/s0735-1097(20)31319-x
https://doi.org/10.1016/s0735-1097(20)31319-x